Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 2, 2006, Pages 135-144

  Adams, David J ^a   Da Silva, Mateus Webba ^a   Flowers, James L ^a   Kohlhagen, Glenda ^c   Pommier, Yves ^c   Colvin, O Michael ^a   Manikumar, Govindarajan ^b   Wani, Mansukh C ^b  

^a DUKE CANCER INSTITUTE   (United States)

^b RTI INTERNATIONAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Camptothecin; Religation assay; Topoisomerase I

Indexed keywords

7 BROMOMETHYL 10 HYDROXY CAMPTOTHECIN; 7 BUTYL 10,11 METHYLENEDIOXY CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; UNCLASSIFIED DRUG;

ALKYLATION; APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA CLEAVAGE; DRUG POTENCY; DRUG SYNTHESIS; GROWTH INHIBITION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; LIPOPHILICITY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; TUMOR CELLS, CULTURED;

EID: 28844451574     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0007-6     Document Type: Article

References (28)

1. Bellarosa D, Ciucci A, Bullo A, Nardelli F, Manzini S, Maggi CA, Goso C (2001) Apoptotic events in a human ovarian cancer cell line exposed to anthracyclines. J Pharmacol Exp Ther 296:276-283
2. Bom D, Curran DP, Kruszewski S, Zimmer SG, Thompson Strode J, Kohlhagen G, Du W, Chavan AJ, Fraley KA, Bingcang AL, Latus LJ, Pommier Y, Burke TG (2000) The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 43:3970-3980
3. Flowers JL, Ludeman SM, Gamcsik MP, Colvin OM, Shao KL, Boal JH, Springer JB, Adams DJ (2000) Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide. Cancer Chemother Pharmacol 45:335-344
4. Gamcsik M, Kasibhatla M, Adams D, Flowers J, Colvin O, Manikumar G, Wani M, Wall M, Kohlhagen G, Pommier Y (2001) Dual role of glutathione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complex. Mol Cancer Ther 1:11-20
5. Giovanella B, Stehlin J, Wall M, Wani M, Nicholas A, Liu L, Silber R, Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048
6. Hirabayashi N, Kim R, Nishiyama M, Aogi K, Saeki S, Toge T, Okada K (1992) Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues (abstract). Proc Am Assoc Cancer Res 33:436
7. Hsiang Y-H, Hertzberg R, Hecht S, Lui R (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878
8. Husain I, Mohler J, Seigler H, Besterman J (1994) Elevation of topoisomerase I messenger RNA, protein and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54:539-546
9. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465-1469
10. Kehrer DFS, Soepenberg O, Loos WJ, Verweij J, Sparreboom A (2001) Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs 12:89-105
11. Li TK, Liu LF (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 41:53-77
12. Matsui S, Endo W, Wrzosek C, Haridas K, Seetharamulu P, Hausheer FH, Rustum YM (1999) Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications. Eur J Cancer 35:984-993
13. Paull K, Shoemaker R, Hodes L, Monks A, Scudiero D, Rubinstein L, Plowman J, Boyd M (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088-1092
14. Pommier Y, Kohlhagen G, Kohn KW, Leteurtre F, Wani MC, Wall ME (1995) Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci USA 92:8861-8865
15. Pommier Y, Kohlhagen G, Laco G, Kroth H, Sayer J, Jerina D (2002) Different effects on human topoisomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site. J Biol Chem 277:13666-13672
16. Pommier Y, Pourquier P, Fan Y, Strumberg D (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400:83-105
17. Potmesil M, Hsiang Y-H, Liu L et al (1988) Topoisomerase I (topo-I) and topoisomerase II (topo-II) levels in high and low grade lymphomas. Proc Am Assoc Cancer Res 29:176
18. Pourquier P, Takebayashi Y, Urasaki Y, Gioffre C, Kohlhagen G, Pommier Y (2000) Induction of topoisomerase I cleavage complexes by 1-beta-D- arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci USA 97:1885-1890
19. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WGJ (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279:1504-1513
20. Sawada S, Nokata K, Furuta T, Yokokura T, Miyasake T (1991) Chemical modification of an antitumor alkaloid camptothecin: Synthesis and antitumor activity of 7-C-substituted camptothecins. Chem Pharm Bull 39:2574-2580
21. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Stewart L (2002) The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 99:15387-15392
22. Valenti M, Nieves-Neira W, Kohlhagen G, Kohn K, Wall M, Wani M, Pommier Y (1997) Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Mol Pharm 52:82-87
23. Van der Zee A, Hollema H, DeJong S, Boonstra H, Gouw A, Willemse P, Zijlstra J, de Vries E (1991) P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51:5915-5920
24. Van Hattum AH, Pinedo HM, Schluper HM, Hausheer FH, Boven E (2000) New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer 88:260-266
25. Vladu B, Woynarowski JM, Manikumar G, Wani MC, Wall ME, Von Hoff DD, Wadkins RM (2000) 7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents. Mol Pharmacol 57:243-251
26. Wall M, Wani M, Cook C, Palmer K, McPhail H, Sim G (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890
27. Wall ME, Wani MC, Nicholas AW, Manikumar G, Tele C, Moore L, Truesdale A, Leitner P, Besterman JM (1993) Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J Med Chem 36:2689-2700
28. Wang XY, Wang LK, Kingsbury WD, Johnson RK, Hecht SM (1998) Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification. Biochemistry 37:9399-9408